Pravastatin sodium is one of a new class of lipid-lowering compounds, the HMG-CoA reductase inhibitors, which reduce cholesterol biosynthesis. These agents are competitive inhibitors of 3-hydroxy-3-methylglutaryl-co-enzyme A (HMG-CoA) reductase, the enzyme catalyzing the early rate-limiting step in cholesterol biosynthesis, conversion of HMG-CoA to mevalonate.

Pravastatin sodium is designated chemically as 1-Naphthalene-heptanoic acid, 1,2,6,7,8,8a-hexahydro- b , d ,6-trihydroxy-2-methyl -8-(2-methyl -1- oxobutoxy)-, monosodium salt,[1 S -[1 a ( b S *, d S *),2 a ,6 a ,8 b ( R *),8a a ]]-. Formula C 23 H 35 NaO 7 , Molecular Weight is 446.52.

Pravastatin sodium is an odorless, white to off-white, fine or crystalline powder. It is a relatively polar hydrophilic compound with a partition coefficient (octanol/water) of 0.59 at a pH of 7.0. It is soluble in methanol and water (>300 mg/ml), slightly soluble in isopropanol, and practically insoluble in acetone, acetonitrile, chloroform, and ether.